AlphAIAlphAI — Financial news for AI agents
SEC EDGARSEP 161 min read$BTSG

Greenwell Scott A. sold $874K of BTSG

Greenwell Scott A. (President, PharMerica) sold 15,099 shares of BrightSpring Health Services, Inc. (BTSG) at $57.91 ($0.87M total) on 2026-09-14 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Greenwell Scott A.
Published Sep 16, 2026, 8:04 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 16, 2026, 8:13 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$BTSG
Bearish
medium confidence
Mentioned
$BTSG
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$BTSGBearishLow
01

Why it matters

While the transaction is newly disclosed, its modest size limits material impact; traders may monitor for further insider activity.

02

Market read

Primary relevance is to BTSG shareholders; broader market effect is negligible.

03

What to watch

Potential upcoming corporate actions or financing needs that prompted the insider to free cash.

Relevance 4/10Novelty 5/10Timing: Filed Sep 16 2026 (same‑day filing)

Background

Form 4 filings disclose insider transactions; a 10b5‑1 plan indicates pre‑arranged sales, often unrelated to company outlook.

Company-level read

Ticker impact

$BTSGBearishMedium confidence
Context

Insider (President) sold 15,099 shares for $874,383 via a 10b5‑1 plan, reducing holdings to 31,246 shares.

Expected impact

Modest short‑term price dip, likely within 1‑2% range.

Evidence & confidence

Sale size is modest relative to market cap, but insider disposition is a negative signal for traders.

Market effects

Sector

Minimal impact on healthcare services sector; similar insider sales have limited sector‑wide effect.

Regional

U.S. market only; no regional ripple.

Global

Low; only relevant to investors tracking BrightSpring.

Counterpoint

What could challenge this read

The sale could be a routine liquidity event under a pre‑arranged plan, not a lack of confidence.

Key entities

  • Company
    BrightSpring Health Services, Inc.

    U.S. healthcare services provider (ticker BTSG).

  • Insider
    Scott A. Greenwell

    President of PharMerica, reporting officer for BrightSpring.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

BTSG insider trading history →

Related articles

AUG 21
$BTSGMedAI 8/10

BrightSpring Stock Up Nearly 59% YTD: Can Its Growth Story Continue?

BrightSpring Health Services (BTSG) stock has risen 59% YTD, outperforming industry and S&P 500. Q2 2026 revenues grew 23% to $3.9B, adjusted EBITDA up 44%. Growth driven by Specialty Pharmacy and Provider Services, with AI/automation improving efficiency. Leverage reduced to 2.15x. 2026 EPS estimates raised to $1.78 (78% growth). Risks include execution challenges and reimbursement pressures.

tradingview.com3 min
AUG 8
$BTSGMedAI 9/10

BrightSpring Health (BTSG) Q2 2026 Earnings Call Transcript

BrightSpring Health Services (BTSG) reported Q2 2026 net revenue of $3.873B, up 23%, and adjusted EBITDA of $205.5M, up 44.2%, with adjusted EPS of $0.45. FY2026 guidance raised to $15.1B-$15.425B revenue and $820M-$845M adjusted EBITDA. Net debt was $1.7B (2.15x leverage).

fool.com6 min
AUG 7
$BTSGMed

5 Revealing Analyst Questions From BrightSpring Health Services’s Q2 Earnings Call

BrightSpring Health Services (BTSG) reported Q2 revenue of $3.87B vs $3.66B expected and adjusted EPS of $0.45 vs $0.40, with adjusted EBITDA of $205.5M. The company raised full-year revenue guidance to $15.26B and EBITDA guidance to $832.5M. Management cited 30% Specialty and Infusion revenue growth and 31% script growth, while Home and Community Pharmacy faced customer exits and regulatory headwinds.

markets.chroniclejournal.com6 min
AUG 4
$BTSGMedAI 8/10

BTSG Raises 2026 Guidance as Specialty and Home Health Drive Growth

BrightSpring Health Services (BTSG) beat Q2 expectations with adjusted EPS of 45 cents (21.6% above consensus) and revenue of $3.87B (+23% YoY). It raised 2026 guidance to $15.10-$15.425B revenue and $820-$845M adjusted EBITDA. Specialty and infusion grew 30.1% and home health revenues rose 30.3%, while pharmacy fell 8% due to IRA impacts.

tradingview.com6 min